Atezolizumab plus bevacizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a cost-effectiveness analysis.
作者信息
Hou Yanli, Wu Bin
机构信息
Department of Radiation Oncology, Ren Ji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 201112, P. R. China.
Medical Decision and Economic Group, Department of Pharmacy, Ren Ji Hospital, South Campus, School of Medicine, Shanghai Jiaotong University, Shanghai, 201112, P. R. China.
出版信息
Cancer Commun (Lond). 2020 Dec;40(12):743-745. doi: 10.1002/cac2.12110. Epub 2020 Nov 7.
Abstract
摘要
相似文献
1
Atezolizumab plus bevacizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a cost-effectiveness analysis.阿替利珠单抗联合贝伐单抗与索拉非尼作为不可切除肝细胞癌一线治疗的成本效益分析
Cancer Commun (Lond). 2020 Dec;40(12):743-745. doi: 10.1002/cac2.12110. Epub 2020 Nov 7.
2
Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗对比索拉非尼用于不可切除或转移性肝细胞癌患者的成本效果分析。
JAMA Netw Open. 2021 Apr 1;4(4):e214846. doi: 10.1001/jamanetworkopen.2021.4846.
3
Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗与索拉非尼作为不可切除肝细胞癌一线治疗的成本效果比较。
JAMA Netw Open. 2021 Feb 1;4(2):e210037. doi: 10.1001/jamanetworkopen.2021.0037.
4
Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.阿替利珠单抗联合贝伐珠单抗与索拉非尼治疗不可切除肝细胞癌患者的患者报告结局（IMbrave150）：一项开放标签、随机、3期试验
Lancet Oncol. 2021 Jul;22(7):991-1001. doi: 10.1016/S1470-2045(21)00151-0. Epub 2021 May 27.
5
Atezolizumab and bevacizumab combination compared with sorafenib as the first-line systemic treatment for patients with unresectable hepatocellular carcinoma: A cost-effectiveness analysis in China and the United states.阿替利珠单抗联合贝伐珠单抗对比索拉非尼作为不可切除肝细胞癌患者的一线系统治疗：中国和美国的成本效果分析。
Liver Int. 2021 May;41(5):1097-1104. doi: 10.1111/liv.14795. Epub 2021 Feb 8.
6
Transarterial Radioembolization Versus Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life.经动脉放射性栓塞与阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌：生活质量恶化时间的匹配调整间接比较。
Adv Ther. 2022 May;39(5):2035-2051. doi: 10.1007/s12325-022-02099-0. Epub 2022 Mar 12.
7
[New approval: Atezolizumab and bevacizumab for first line of unresecable hepatocellular carcinoma].[新批准：阿替利珠单抗和贝伐珠单抗用于不可切除肝细胞癌一线治疗]
Bull Cancer. 2021 Feb;108(2):139-140. doi: 10.1016/j.bulcan.2020.11.011. Epub 2021 Feb 2.
8
Cost-effectiveness analysis of atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in advanced hepatocellular carcinoma in Singapore.新加坡晚期肝细胞癌一线治疗中阿替利珠单抗联合贝伐珠单抗对比索拉非尼的成本效果分析。
Expert Rev Pharmacoecon Outcomes Res. 2024 Jun;24(5):631-641. doi: 10.1080/14737167.2024.2319607. Epub 2024 May 22.
9
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.IMbrave150研究的更新疗效和安全性数据：阿替利珠单抗联合贝伐珠单抗对比索拉非尼治疗不可切除肝细胞癌。
J Hepatol. 2022 Apr;76(4):862-873. doi: 10.1016/j.jhep.2021.11.030. Epub 2021 Dec 11.
10
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis.阿替利珠单抗联合贝伐珠单抗对比仑伐替尼或索拉非尼用于非病毒性不可切除肝细胞癌：一项国际倾向性评分匹配分析。
ESMO Open. 2022 Dec;7(6):100591. doi: 10.1016/j.esmoop.2022.100591. Epub 2022 Oct 6.
引用本文的文献
1
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for patients with unresectable hepatocellular carcinoma: a cost-utility analysis in China and the United States.卡瑞利珠单抗联合瑞沃替尼与索拉非尼作为不可切除肝细胞癌患者一线治疗的成本-效用分析：中国和美国的研究
Front Pharmacol. 2025 May 1;16:1404389. doi: 10.3389/fphar.2025.1404389. eCollection 2025.
2
Cost-effectiveness of atezolizumab plus bevacizumab versus sorafenib as first-line therapy in unresectable hepatocellular carcinoma in the US and Chinese setting: a modelling comparison study.在美国和中国背景下，阿替利珠单抗联合贝伐单抗与索拉非尼作为不可切除肝细胞癌一线治疗的成本效益：一项建模比较研究。
BMJ Open. 2025 Mar 6;15(3):e094804. doi: 10.1136/bmjopen-2024-094804.
3
Cost-effectiveness of camrelizumab plus rivoceranib versus sorafenib as first-line treatment of unresectable hepatocellular carcinoma.卡瑞利珠单抗联合阿伐替尼与索拉非尼作为不可切除肝细胞癌一线治疗的成本效益
Therap Adv Gastroenterol. 2025 Jan 2;18:17562848241310314. doi: 10.1177/17562848241310314. eCollection 2025.
4
Cost-effectiveness of camrelizumab plus rivoceranib for advanced hepatocellular carcinoma in the context of regional disparities in China.在中国地区差异背景下，卡瑞利珠单抗联合阿伐替尼治疗晚期肝细胞癌的成本效益
Front Oncol. 2024 Dec 6;14:1491404. doi: 10.3389/fonc.2024.1491404. eCollection 2024.
5
Cost-Effectiveness Analysis of Camrelizumab Plus Rivoceranib Versus Sorafenib as a First-Line Therapy for Unresectable Hepatocellular Carcinoma in the Chinese Health Care System.卡瑞利珠单抗联合瑞戈非尼对比索拉非尼作为中国卫生体系下不可切除肝细胞癌一线治疗的成本效果分析。
Clin Drug Investig. 2024 Mar;44(3):149-162. doi: 10.1007/s40261-024-01343-5. Epub 2024 Feb 1.
6
Safety and Efficacy of Atezolizumab and Bevacizumab Combination as a First Line Treatment of Advanced Hepatocellular Carcinoma.阿替利珠单抗与贝伐单抗联合作为晚期肝细胞癌一线治疗的安全性和有效性
J Hepatocell Carcinoma. 2023 Oct 2;10:1689-1708. doi: 10.2147/JHC.S347932. eCollection 2023.
7
Comparative analysis of disease modelling for health economic evaluations of systemic therapies in advanced hepatocellular carcinoma.比较分析系统治疗晚期肝细胞癌的卫生经济评价中的疾病建模。
PLoS One. 2023 Oct 5;18(10):e0292239. doi: 10.1371/journal.pone.0292239. eCollection 2023.
8
Cost-effectiveness analysis of adding transarterial chemoembolisation to lenvatinib as first-line treatment for advanced hepatocellular carcinoma in China.中国晚期肝细胞癌一线治疗中添加经动脉化疗栓塞术联合仑伐替尼的成本效果分析。
BMJ Open. 2023 Sep 26;13(9):e074245. doi: 10.1136/bmjopen-2023-074245.
9
Cost-effectiveness analysis of transarterial chemoembolization combined with lenvatinib as the first-line treatment for advanced hepatocellular carcinoma.经动脉化疗栓塞联合乐伐替尼作为晚期肝细胞癌一线治疗的成本效益分析
Front Pharmacol. 2023 Sep 7;14:1219694. doi: 10.3389/fphar.2023.1219694. eCollection 2023.
10
Beneficial Effect of Combining Radiotherapy and Transarterial Chemoembolization on Patient Survival in Hepatocellular Carcinomas and Macrovascular Invasion Treated with Sorafenib.索拉非尼治疗的伴有大血管侵犯的肝细胞癌患者中，放疗联合经动脉化疗栓塞对患者生存的有益影响
Cancers (Basel). 2023 May 10;15(10):2687. doi: 10.3390/cancers15102687.
本文引用的文献
1
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌。
N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.
2
Using strategic price negotiations to contain costs and expand access to medicines in China.利用战略价格谈判来控制成本并扩大中国药品的可及性。
BMJ Glob Health. 2020 Jan 31;5(1):e002256. doi: 10.1136/bmjgh-2019-002256. eCollection 2020.
3
Efficacy of treatment regimens for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials.晚期肝细胞癌治疗方案的疗效：随机对照试验的网状Meta分析
Medicine (Baltimore). 2019 Oct;98(40):e17460. doi: 10.1097/MD.0000000000017460.
4
Immunotherapy in Hepatocellular Carcinoma: Is There a Light at the End of the Tunnel?肝细胞癌的免疫疗法：隧道尽头有曙光吗？
Cancers (Basel). 2019 Jul 30;11(8):1078. doi: 10.3390/cancers11081078.
5
Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.全球、地区和国家残疾调整生命年（DALYs）359 种疾病和伤害以及 195 个国家和地区 1990-2017 年的健康期望寿命（HALE）：2017 年全球疾病负担研究的系统分析。
Lancet. 2018 Nov 10;392(10159):1859-1922. doi: 10.1016/S0140-6736(18)32335-3.
6
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018：GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
7
Sustainability and affordability of cancer drugs: a novel pricing model.癌症药物的可持续性与可负担性：一种新型定价模式
Nat Rev Clin Oncol. 2018 Jul;15(7):405-406. doi: 10.1038/s41571-018-0027-x.
8
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.乐伐替尼与索拉非尼用于不可切除肝细胞癌患者一线治疗的比较：一项随机、III 期非劣效性试验。
Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1.
9
Hepatocellular carcinoma.肝细胞癌。
Lancet. 2018 Mar 31;391(10127):1301-1314. doi: 10.1016/S0140-6736(18)30010-2. Epub 2018 Jan 5.
Zotero 插件